242 related articles for article (PubMed ID: 18638092)
21. Catheter lock heparin concentration: effects on tissue plasminogen activator use in tunneled cuffed catheters.
Holley JL; Bailey S
Hemodial Int; 2007 Jan; 11(1):96-8. PubMed ID: 17257362
[TBL] [Abstract][Full Text] [Related]
22. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement.
Yevzlin AS; Sanchez RJ; Hiatt JG; Washington MH; Wakeen M; Hofmann RM; Becker YT
Semin Dial; 2007; 20(4):351-4. PubMed ID: 17635828
[TBL] [Abstract][Full Text] [Related]
23. Haemostatic complications in haemodialysis patients: effect of type of vascular access and dialysis filter.
Yu A; Egberg N; Jacobson SH
Scand J Clin Lab Invest; 2003; 63(2):127-33. PubMed ID: 12751694
[TBL] [Abstract][Full Text] [Related]
24. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
[TBL] [Abstract][Full Text] [Related]
25. Femoral vein tunneled catheters as a last resort to vascular access: report of five cases and review of literature.
Budruddin M; Mohsin N; Amitabh J; Ehab M; Pramod K; Abbas P; Khalil M; Al-Lawati S
Ren Fail; 2009; 31(4):320-2. PubMed ID: 19462282
[TBL] [Abstract][Full Text] [Related]
26. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients.
Weijmer MC; van den Dorpel MA; Van de Ven PJ; ter Wee PM; van Geelen JA; Groeneveld JO; van Jaarsveld BC; Koopmans MG; le Poole CY; Schrander-Van der Meer AM; Siegert CE; Stas KJ;
J Am Soc Nephrol; 2005 Sep; 16(9):2769-77. PubMed ID: 16033861
[TBL] [Abstract][Full Text] [Related]
27. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection.
Jaffer Y; Selby NM; Taal MW; Fluck RJ; McIntyre CW
Am J Kidney Dis; 2008 Feb; 51(2):233-41. PubMed ID: 18215701
[TBL] [Abstract][Full Text] [Related]
28. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial.
Saxena AK; Panhotra BR; Sundaram DS; Morsy MN; Al-Ghamdi AM
Nephrology (Carlton); 2006 Aug; 11(4):299-305. PubMed ID: 16889569
[TBL] [Abstract][Full Text] [Related]
29. Changes in fibrinolytic activity during the course of a single hemodialysis session.
Kurz H; Lerner RG; Weseley S; Nelson JC
Clin Nephrol; 1985 Jul; 24(1):1-4. PubMed ID: 4040447
[TBL] [Abstract][Full Text] [Related]
30. Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.
Mathur M; Desai N; Sharma J; Rao SP; Goldman GM
Pediatr Crit Care Med; 2005 Jan; 6(1):79-82. PubMed ID: 15636665
[TBL] [Abstract][Full Text] [Related]
31. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
Daeihagh P; Jordan J; Chen J; Rocco M
Am J Kidney Dis; 2000 Jul; 36(1):75-9. PubMed ID: 10873875
[TBL] [Abstract][Full Text] [Related]
33. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
Salobir B; Sabovic M; Zupan IP; Ponikvar JB
Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
[TBL] [Abstract][Full Text] [Related]
34. Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.
Grudzinski L; Quinan P; Kwok S; Pierratos A
Nephrol Dial Transplant; 2007 Feb; 22(2):471-6. PubMed ID: 17065193
[TBL] [Abstract][Full Text] [Related]
35. [Catheter lock solution--taurolock for prevention of catheter-related bacteremia in hemodialysis patients].
Geron R; Tanchilevski O; Kristal B
Harefuah; 2006 Dec; 145(12):881-4, 943. PubMed ID: 17220025
[TBL] [Abstract][Full Text] [Related]
36. What are the factors contributing to the changes in tissue-type plasminogen activator during haemodialysis?
Opatrný K; Opatrný K; Vít L; Racek J; Válek A
Nephrol Dial Transplant; 1991; 6 Suppl 3():26-30. PubMed ID: 1775262
[TBL] [Abstract][Full Text] [Related]
37. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
Vercaigne LM; Zacharias J; Bernstein KN
Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
[TBL] [Abstract][Full Text] [Related]
38. Recombinant tissue plasminogen activator to declot dialysis fistulas.
Boobes Y; al Hassan H; Neglen P; Obeid K; Denour N
J Nephrol; 1997; 10(2):107-10. PubMed ID: 9238617
[TBL] [Abstract][Full Text] [Related]
39. Urokinase efficacy in the restoration of hemodialysis catheter function.
Meers C; Toffelmire EB
J CANNT; 1998; 8(2):17-9. PubMed ID: 9807329
[TBL] [Abstract][Full Text] [Related]
40. Managing catheter dysfunction for better patient outcomes: a team approach.
Dinwiddie LC
Nephrol Nurs J; 2004; 31(6):653-60, 671; quiz 661-2. PubMed ID: 15686329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
